Atrin 20logo 20white 20final
Atrin 20logo 20white 20final

Atrin pharmaceuticals

Targeted small molecule therapeutics for treating cancer

  • Stage Product In Development
  • Industry Biotechnology
  • Location Doylestown, PA, US
  • Currency USD
  • Founded January 2011
  • Employees 5
  • Website

Company Summary

Atrin is a dynamic biopharmaceutical firm focused on the discovery and development of cancer medications with potential to improve positive treatment results while minimizing the side effects of traditional therapy. Using a groundbreaking technology developed and licensed in association with UPenn in a royalty-free transaction, Atrin is developing a portfolio of drug candidates targeting several oncological indications by multiple MOA


  • Default avatar
    Oren Gilad

    Dr. Gilad is a dynamic serial-entrepreneur and business leader who has built and profitably sold two small businesses. He is an innovator, strategic thinker, planner, and problem solver. He has leadership skills, proven execution skills and extensive hands-on experience across the different phases of drug R&D. He authored several high impact scientific articles and was recently named 2015 EY Entrepreneur Of The Year Greater Philadelphia Finalist

  • Bernard Rudnick is a founder and managing partner of CapGenic Advisors and a member of several investment groups. He is an experienced Biotech C-Level executive who facilitated exits and transactions valued over $7B. With 36 years of experience in executive-level strategy, finance, and management, Mr. Rudnick has senior merger, acquisition, capital formation and licensing leadership experience with companies ranging from start-up to Fortune 50

  • Default avatar
    Henry J. Breslin
    Head of Medicianl Chemistry

    Hank has over 25 years experience in the industry. He is the inventor of Viberzi, which recently was approved by the FDA for treatment of IBS-d. After J&J Hank worked at Cephalon were he focused on the kinase field and where he designed and prepared one of the most potent Anaplastic Lymphoma Kinase (ALK) inhibitors reported to date. Now at Atrin Pharmaceuticals, Hank is again focused on cancer therapeutics, with major emphasis in the kinase arena

  • Default avatar
    Laura R. Butler
    Head of Biology

    Dr. Butler’s research career has centered on cancer biology. She lead the generation and characterization of active protein targets for high throughput drug screening and her pioneered work on the role of ubiquitin in the DNA damage response was published in Nature. She continued her research at the University of Birmingham before joining a lab at UPenn where was able to further work on the role of DNA damage pathways in cancer biology

Previous Investors

  • Default avatar
    This information is confidential